Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events & laboratory abnormalities. 12 Weeks [clinicaltrials_resource:1e9d619cb2f4cda402354f1f06f2a796]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events & laboratory abnormalities. 12 Weeks [clinicaltrials_resource:1e9d619cb2f4cda402354f1f06f2a796]
Bio2RDF identifier
1e9d619cb2f4cda402354f1f06f2a796
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1e9d619cb2f4cda402354f1f06f2a796
measure [clinicaltrials_vocabulary:measure]
Subject self assessment of imp ...... ts & laboratory abnormalities.
time frame [clinicaltrials_vocabulary:time-frame]
identifier
clinicaltrials_resource:1e9d619cb2f4cda402354f1f06f2a796
title
Subject self assessment of imp ...... ratory abnormalities. 12 Weeks
@en
type
label
Subject self assessment of imp ...... d619cb2f4cda402354f1f06f2a796]
@en